Associated Genetic Biomarkers
HLA-DRA status serves as an inclusion eligibility criteria in 3 clinical trials, of which 3 are open and 0 are closed. Of the trials that contain HLA-DRA status as an inclusion criterion, 2 are phase 1 (2 open) and 1 is phase 2 (1 open).
Trials with HLA-DRA status in the inclusion eligibility criteria most commonly target myelodysplastic syndromes, acute myeloid leukemia, and melanoma .
The most frequent alterations to serve as inclusion eligibility criteria are HLA-DRA Expression and HLA-DRA Overexpression .
Donor-derived wt1/prame/ny-eso-1/survivin-specific t-lymphocytes, decitabine, nivolumab, pembrolizumab, and relatlimab are the most frequent therapies in trials with HLA-DRA as an inclusion criteria .
Significance of HLA-DRA in Diseases
Acute Myeloid Leukemia +
HLA-DRA is an inclusion criterion in 2 clinical trials for acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain HLA-DRA status and acute myeloid leukemia as inclusion criteria, 2 are phase 1 (2 open) .
Myelodysplastic Syndromes +
HLA-DRA is an inclusion criterion in 2 clinical trials for myelodysplastic syndromes, of which 2 are open and 0 are closed. Of the trials that contain HLA-DRA status and myelodysplastic syndromes as inclusion criteria, 2 are phase 1 (2 open) .
HLA-DRA is an inclusion criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains HLA-DRA status and melanoma as inclusion criteria, 1 is phase 2 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.